MedTrace Logo

Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

NCT00176423 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 117

Last updated 2020-12-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine whether adjunctive galantamine is effective in the treatment of cognitive impairments in patients with schizophrenia.

Conditions

Interventions

DRUG

galantamine

see arm/group description

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Ortho-McNeil Neurologics, Inc.

    collaborator INDUSTRY

  • University of Maryland, Baltimore

    lead OTHER

Principal Investigators

  • Robert W Buchanan, M.D. · University of Maryland Baltimore School of Medicine, Maryland Psychiatric Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-05-31
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00176423 on ClinicalTrials.gov